<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00229333</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-03-3124-AS-CTIL</org_study_id>
    <nct_id>NCT00229333</nct_id>
  </id_info>
  <brief_title>Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia</brief_title>
  <official_title>Exploratory Study to Assess the Efficacy of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia and Mixed Vascular and Alzheimer’s Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheba Medical Center</source>
  <brief_summary>
    <textblock>
      The goal of the present study is to compare the effectiveness of the active (S)-enantiomer of
      citalopram, escitalopram with placebo in the treatment of patients with depressive syndrome
      complicating Alzheimer’s dementia (AD), vascular dementia (VD) or mixed dementia (MD), for 8
      weeks of double-blind treatment.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2004</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cornell Scale for Depression in Dementia (CSDD) total score</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cohen-Mansfield Agitation Inventory (CMAI; Cohen-Mansfield et al. 1989)</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Depressive Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject meets criteria for the diagnosis of Alzheimer’s dementia, or vascular
             dementia, or mixed alzheimer's and vascular dementia, according to Diagnostic and
             Statistical for Mental Disorders, Fourth Edition (DSM-IV) criteria.

          -  Subject meets the following criteria for depressive syndrome: DSM-IV criteria for
             major depressive episode; and Cornell Scale of Depression in Dementia is 18 or more.

          -  The depressive syndrome has been present for at least two weeks preceding study entry
             (Visit 1).

          -  The depressive syndrome must be at least moderate in severity at Visit 1 and Visit 2
             (cause the subject impairment in functional capacity) and in the opinion of the
             investigator require pharmacological intervention.

          -  Score on the Mini Mental State Examination (MMSE) of 10-26 at Visit 1 and at Visit 2.

          -  Other possible reasons for the subject’s depressive symptoms, for example, medications
             or other medical conditions (such as pain, infection, cancer of the pancreas, etc.),
             have been excluded as an etiology.

        Exclusion Criteria:

        General Exclusion Criteria:

          -  Subjects who need placebo run-in period, and/or their caregivers are unable to comply
             with Study Period I medication to the extent that drug compliance in the remainder of
             the study would be compromised as determined by the investigator.

          -  Investigators, site personnel directly affiliated with this study, and their immediate
             families. Immediate family is defined as a spouse, parent, child or sibling, whether
             biological or legally adopted.

        Diagnostic Exclusion Criteria:

          -  Schizophrenia

          -  Subjects who are judged clinically to be at serious suicidal risk at Visit 1.

          -  Subjects who have clinically significant psychotic symptoms at Visit 1.

          -  Subject has a serious neurological condition other than AD, VD or MD including, but
             not limited to: traumatic (head-brain) dementia, space-occupying lesion, relevant
             structural abnormalities on brain imaging, etc.

          -  Subject who underwent CVA for 3 months.

          -  Subject is doing well on a current antidepressant drug regimen.

        Exclusionary Concurrent or Historical Illness:

          -  Subjects with severe hepatic or renal insufficiency.

          -  Hypo/hyperthyroidism

          -  B-12 deficiency

        Exclusionary Concomitant or Historical Medications:

          -  Participation in a clinical trial of another investigational drug within 30 days prior
             to study entry (Visit 1) and/or any concurrent investigational study.

          -  Subjects with a history of severe adverse reaction to citalopram or escitalopram.

          -  Concomitant medication as specified.

          -  Previous treatment with escitalopram unless, in the opinion of the investigator, the
             patient’s previous treatment was inadequate in dose and/or duration to provide an
             accurate assessment of the therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Sverdlik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Sverdlik, MD</last_name>
    <phone>972-54-4718424</phone>
    <email>annasver@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Sverdlik, MD</last_name>
      <phone>972-54-4718424</phone>
      <email>annasver@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Aviva Cohen, BA</last_name>
      <phone>972-3-5305910</phone>
    </contact_backup>
    <investigator>
      <last_name>Anna Sverdlik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2005</study_first_submitted>
  <study_first_submitted_qc>September 27, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2005</study_first_posted>
  <last_update_submitted>August 28, 2006</last_update_submitted>
  <last_update_submitted_qc>August 28, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2006</last_update_posted>
  <keyword>Escitalopram</keyword>
  <keyword>Depression</keyword>
  <keyword>Dementia</keyword>
  <keyword>Treatment</keyword>
  <keyword>Depressive Syndrome in Alzheimer’s Disease</keyword>
  <keyword>Depressive Syndrome in Vascular Dementia</keyword>
  <keyword>Depressive Syndrome in Mixed Vascular and Alzheimer’s Dementia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Dementia, Vascular</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 19, 2009</submitted>
    <returned>August 26, 2009</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

